Cargando…

P584: VENETOCLAX PLUS HOMOHARRINGTONINE-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR ADULTS WITH ACUTE MYELOID LEUKAEMIA: A MULTICENTRE, SINGLE-ARM, PHASE 2 TRIAL

Detalles Bibliográficos
Autores principales:	Wang, Huafeng, Yang, Min, Tong, Hongyan, Lou, Yinjun, Zhu, Honghu, Han, Yue, Qian, Jiejin, Mao, Liping, Yang, Chunmei, Lu, Ying, Zhou, Xinping, Shou, Lihong, Meng, Haitao, Zhou, De, Yu, Wenjuan, LI, LI, Jin, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428700/ http://dx.doi.org/10.1097/01.HS9.0000969240.88472.88

Ejemplares similares

Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms
por: Yuan, Fangfang, et al.
Publicado: (2022)

P564: HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML
por: Luo, Xiao-Hua, et al.
Publicado: (2023)

Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
por: Zhang, Xiang, et al.
Publicado: (2021)

Outcomes of venetoclax combined with homoharringtonine and cytarabine in fit adults patients with de novo adverse‐risk acute myeloid leukaemia: A single‐centre retrospective analysis
por: Song, Bao‐Quan, et al.
Publicado: (2023)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
por: Jin, Hua, et al.
Publicado: (2023)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
por: Yuan, Linyu, et al.
Publicado: (2023)

Treatment of STAT5b-RARA positive acute promyelocytic leukemia by Venetoclax combining with homoharringtonine, cytarabine: A case report and literature review
por: Zhang, Guangji, et al.
Publicado: (2022)

The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2017)

Correction: The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2019)

Homoharringtonine and omacetaxine for myeloid hematological malignancies
por: Lü, Shuqing, et al.
Publicado: (2014)

Characterization of the Newly Established Homoharringtonine- (HHT-) Resistant Cell Lines and Mechanisms of Resistance
por: Li, Fenglin, et al.
Publicado: (2022)

Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia
por: Wang, Huafeng, et al.
Publicado: (2022)

The Metabolic Signature of AML Cells Treated With Homoharringtonine
por: Zhang, Yulong, et al.
Publicado: (2022)

A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia
por: Lévy, V, et al.
Publicado: (2006)

Long‐term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine‐venetoclax
por: Maravalle, Denise, et al.
Publicado: (2022)

SUN-584 Unusual Presentation Of Myxedema Coma
por: Murati, Jonila, et al.
Publicado: (2019)

SUN-584 Micrornas in Brown and White Adipocytes
por: Dimitri, Federica, et al.
Publicado: (2020)

Curcumin in combination with homoharringtonine suppresses lymphoma cell growth by inhibiting the TGF-β/Smad3 signaling pathway
por: Zhang, Yu, et al.
Publicado: (2021)

The Natural Compound Homoharringtonine Presents Broad Antiviral Activity In Vitro and In Vivo
por: Dong, Hui-Jun, et al.
Publicado: (2018)

Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine
por: Andersen, Petter I., et al.
Publicado: (2019)

The clinical impact of IKZF1 mutation in acute myeloid leukemia
por: Zhang, Xiang, et al.
Publicado: (2023)

Correction for: Curcumin in combination with homoharringtonine suppresses lymphoma cell growth by inhibiting the TGF-β/Smad3 signaling pathway
por: Zhang, Yu, et al.
Publicado: (2022)

MON-584 Albuminuria and Obesity - Which Are the Associated Factors?
por: Costa, Cláudia Fernandes, et al.
Publicado: (2020)

584. Ventricular assist device infections with Pseudomonas aeruginosa
por: Roberts, Scott C, et al.
Publicado: (2020)

Inhibition of bromodomain and extra‐terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia
por: Carrà, Giovanna, et al.
Publicado: (2019)

Practical management of tumour lysis syndrome in venetoclax‐treated patients with chronic lymphocytic leukaemia
por: Gribben, John G.
Publicado: (2019)

PB1779: DEVELOPING NOVEL SYNERGISTIC DRUG COMBINATIONS WITH VENETOCLAX IN ACUTE MYELOID LEUKAEMIA
por: Harrigan, R., et al.
Publicado: (2022)

High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial
por: Li, Jun, et al.
Publicado: (2022)

Synergistic Lethality Effects of Apatinib and Homoharringtonine in Acute Myeloid Leukemia
por: Shi, Yuanfei, et al.
Publicado: (2022)

The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia
por: Shi, Yuanfei, et al.
Publicado: (2021)

Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
por: Báez-Gutiérrez, Nerea, et al.
Publicado: (2021)

Case report: Successful treatment of refractory immune thrombocytopenia in chronic lymphocytic leukaemia with venetoclax monotherapy
por: Woo, Timothy, et al.
Publicado: (2023)

ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3 ‐ITD
por: Qian, Yu, et al.
Publicado: (2023)

Homoharringtonine Exerts an Antimyeloma Effect by Promoting Excess Parkin-Dependent Mitophagy
por: Zhang, Yanyu, et al.
Publicado: (2020)

Ocular toxoplasmosis during frontline venetoclax therapy for chronic lymphocytic leukaemia – more than meets the eye
por: Bennett, Rory, et al.
Publicado: (2023)

Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells
por: Chen, Jian, et al.
Publicado: (2017)

Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
por: Ling, Qing, et al.
Publicado: (2023)

584. Investigation of the Association Between Neurocognitive Function and Depression in HIV Infection
por: Mumford, Brigid, et al.
Publicado: (2018)

MON-584 Iodine Nutrition Status in Pregnancy: Is the Situation in Poland Improving?
por: Trofimiuk-Muldner, Malgorzata, et al.
Publicado: (2019)

Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor
por: Wierda, William G., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o2jbmi8u8m6pi840ciqfjujq0j